Novel breast cancer risk alleles and endometrial cancer risk.
Genome-wide association studies have identified several novel risk alleles for breast cancer. We hypothesized that genetic variants that are associated with breast cancer, a hormone-related disease, would also be associated with endometrial cancer, another hormone-related disease. We conducted a case-control study nested within the Nurses' Health Study and the Women's Health Study to investigate the associations between these 7 newly identified risk alleles for breast cancer and endometrial cancer risk using 692 invasive endometrial cancer cases and 1,723 matched controls. We used conditional logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs) to assess the risk of endometrial cancer. In contrast to the breast cancer findings, we did not observe an increased risk of endometrial cancer. We observed an inverse association among rs2981582 (FGFR2) variant carriers [OR= 0.75 (95% CI: 0.60-0.95)]. We also observed a nonsignificant inverse association with rs889312 (MAP3K1) variant carriers [OR = 0.85 (95% CI: 0.68-1.05)] and rs1219648 (FGFR2) variant carriers [OR= 0.86 (95% CI: 0.69-1.06) and endometrial cancer risk. We did not observe associations with the other single nucleotide polymorphisms (SNPs) and endometrial cancer risk. Replication studies investigating these polymorphisms and endometrial cancer risk are warranted. However, our findings do suggest the potential importance of biological differences between endometrial and breast cancer with respect to the genes identified in the scans. The molecular mechanisms underlying these differences remain to be defined.
McGrath
Monica
M
Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Harvard School of Public Health, MA 02115, USA. monica.mcgrath@channing.harvard.edu
Lee
I-Min
IM
Buring
Julie
J
Hunter
David J
DJ
De Vivo
Immaculata
I
D000328:Adult; D000483:Alleles; D001943:Breast Neoplasms / Q000235:genetics*; D016022:Case-Control Studies; D016001:Confidence Intervals; D016889:Endometrial Neoplasms / Q000235:genetics* / Q000473:pathology; D005260:Female; D005838:Genotype; D006801:Humans; D016015:Logistic Models; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009726:Nurses; D016017:Odds Ratio; D020641:Polymorphism, Single Nucleotide; D018570:Risk Assessment; D012307:Risk Factors; D016387:Women's Health
Mol Cell Biochem. 1993 Nov;127-128:201-9
7935352
PLoS Biol. 2008 May 6;6(5):e108
18462018
Mol Hum Reprod. 2001 Jan;7(1):65-72
11134362
Br J Cancer. 1992 Aug;66(2):273-80
1380281
Science. 1994 Mar 18;263(5153):1625-9
8128251
Nature. 2007 Jun 28;447(7148):1087-93
17529967
Int J Cancer. 1994 Nov 15;59(4):460-2
7960212
J Cell Physiol. 2007 Mar;210(3):720-31
17133345
Nat Genet. 2007 Jul;39(7):865-9
17529974
Stat Med. 2002 Jan 15;21(1):35-50
11782049
Cytokine Growth Factor Rev. 2005 Apr;16(2):179-86
15863033
Am J Obstet Gynecol. 2000 Jan;182(1 Pt 1):23-9
10649152
Nat Genet. 2008 Jun;40(6):703-6
18438407
PLoS Genet. 2008 Apr 25;4(4):e1000054
18437204
Oncogene. 2007 Nov 1;26(50):7158-62
17525745
Cancer Epidemiol Biomarkers Prev. 1996 Jun;5(6):411-7
8781735
Nat Genet. 2007 Jul;39(7):870-4
17529973
Lab Invest. 1997 Oct;77(4):389-402
9354773
Nature. 1994 Sep 1;371(6492):75-80
8072530